1. No category

TEVA TO DEVELOP UNIQUE WEARABLE TECH AND MACHINE LEARNING PLATFORM FOR CONTINUOUS
MEASUREMENT & ANALYSIS OF HUNTINGTON DISEASE SYMPTOMS IN COLLABORATION WITH INTEL
Platform aims to enhance understanding of disease progression and impact of treatment
Jerusalem, September 15, 2016 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today
announces a collaboration with Intel Corporation to develop a unique wearable device and machine
learning platform for use in Huntington disease (HD). This platform will continuously monitor and
analyze key symptoms that impact daily living, in an effort to better understand disease progression and
improve treatment evaluation.
Teva, working in collaboration with Intel, will deploy this novel technology platform for the first time in a
sub-study within the ongoing Phase 2 Open-Pride HD Study. As part of this, patients will be asked to use
a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure
their general functioning and movement. These data will be wirelessly streamed to a cloud-based
platform specifically developed by Intel to analyze data from wearable devices. Proprietary algorithms
will then translate these data, in near real-time, into objective scores of motor symptom severity. The
study will start towards the end of the year and will take place in centers in the US and Canada.
This collaboration will leverage Intel's capabilities in analytics and algorithm development for movement
detection, together with Teva's deep knowledge and experience in HD treatment and research. HD is a
devastating illness that is desperate for treatment options, requiring innovative ways to continuously
and remotely assess and quantify symptoms in a way that can provide meaningful and actionable
feedback to doctors, patients and caregivers.
"The aim of this important project is to provide continuous objective data on the impact of Huntington
disease on the patient, and, by extension, a clear understanding of the impact of treatment on patients'
quality of life," said Michael Hayden, President of Teva Global R&D and Chief Scientific Officer. "Current
measurement of symptoms is largely based on observation when the patient sees the doctor. This
technology now provides us with an opportunity to have continuous monitoring. This unique technology
could complement future trials in HD."
“Patients generate data based on their day-to-day experiences that can help in improving disease
management — even something as simple as wearing a smart watch can add useful insight,” said Jason
Waxman, Corporate Vice President and General Manager of the Datacenter Solutions Group at Intel.
“The complexity of analyzing these data streams requires a platform for machine learning, to help drive
IR Contacts:
Kevin C. Mannix
Ran Meir
Tomer Amitai
United States
United States
Israel
(215) 591-8912
(215) 591-3033
972 (3) 926-7656
PR Contacts:
Iris Beck Codner
Denise Bradley
Nancy Leone
Israel
United States
United States
972 (3) 926-7687
(215) 591-8974
(215) 284-0213
the pharmaceutical industry towards faster, better clinical trials, potentially leading to new treatments
for patients.”
This cloud-based solution for analyzing wearable device data is being developed using the open-source
Intel Trusted Analytics Platform (TAP), a software platform optimized for performance and security to
accelerate the creation of advanced analytics and machine learning solutions. Initial development was
done in collaboration with The Michael J. Fox Foundation for use in Parkinson's disease research.
About Huntington disease
Huntington disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and
uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. The
classic onset of HD symptoms typically occurs in middle age, but the disease also manifests in children
and the elderly. HD is the most common genetic cause of abnormal involuntary writhing movements
called chorea. Disease progression is characterized by a gradual decline in motor control, cognition and
mental stability and generally results in death within 15‐25 years of clinical diagnosis.
HD is a genetic disease, passed from parent to child through a gene mutation. Each child of an HD parent
has a 50-50 chance of inheriting the HD gene. If a child does not inherit the HD gene, he or she will not
develop the disease and cannot pass it to subsequent generations. A person who inherits the HD gene
will sooner or later develop the disease. According to the World Health Organization, Huntington
disease affects about five to seven people per 100,000 in Western countries.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company
that delivers high-quality, patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio
of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva
integrates its generics and specialty capabilities in its global research and development division to create
new ways of addressing unmet patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information,
visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
IR Contacts:
Kevin C. Mannix
Ran Meir
Tomer Amitai
United States
United States
Israel
(215) 591-8912
(215) 591-3033
972 (3) 926-7656
PR Contacts:
Iris Beck Codner
Denise Bradley
Nancy Leone
Israel
United States
United States
972 (3) 926-7687
(215) 591-8974
(215) 284-0213
This release contains forward-looking statements, which are based on management’s current beliefs and
expectations and involve a number of known and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results, performance or achievements expressed or
implied by such forward-looking statements. Important factors that could cause or contribute to such differences
include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for
our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a
generic version); our ability to integrate Allergan plc’s worldwide generic pharmaceuticals business (“Actavis
Generics”) and to realize the anticipated benefits of the acquisition (and the timing of realizing such benefits); the fact
that following the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than
previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional
transactions or incur additional indebtedness as a result of the substantial amount of debt incurred to finance the
Actavis Generics acquisition; the fact that for a period of time following the Actavis Generics acquisition, we will have
significantly less cash on hand than previously, which could adversely affect our ability to grow; the possibility of
material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA
investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty
and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control
problems damage our reputation for quality production and require costly remediation; increased government scrutiny
in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to
protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and
pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations
into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political
or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in
our supply chain or problems with internal or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our information technology systems or breaches of our
data security; competition for our specialty pharmaceutical businesses from companies with greater resources and
capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other
markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure
to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract
additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially
significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely
affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that
are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on
which they are made and we assume no obligation to update or revise any forward-looking statements or other
information, whether as a result of new information, future events or otherwise.
###
IR Contacts:
Kevin C. Mannix
Ran Meir
Tomer Amitai
United States
United States
Israel
(215) 591-8912
(215) 591-3033
972 (3) 926-7656
PR Contacts:
Iris Beck Codner
Denise Bradley
Nancy Leone
Israel
United States
United States
972 (3) 926-7687
(215) 591-8974
(215) 284-0213
‫טבע תפתח פלטפורמת טכנולוגיה לבישה (‪ )wearable‬ולמידה (‪ )machine learning‬ייחודית למדידה‬
‫וניתוח מתמשכים של תסמיני מחלת הנטינגטון בשיתוף פעולה עם אינטל‬
‫מטרת הפלטפורמה לשפר את ההבנה של התקדמות המחלה והשפעת הטיפול‬
‫ירושלים‪ 15 ,‬בספטמבר ‪ – 2016‬טבע תעשיות פרמצבטיות בע"מ (‪ NYSE‬ו‪ )TEVA :TASE-‬הודיעה היום על‬
‫שיתוף פעולה עם חברת אינטל לפיתוח פלטפורמת טכנולוגיה לבישה ומכונה לומדת ייחודית לשימוש במחלת‬
‫הנטינגטון‪ .‬פלטפורמה זו תנטר ותנתח סימפטומים מרכזיים המשפיעים על חי יומיום במטרה להבין טוב יותר את‬
‫התקדמות המחלה ולשפר את אבחנות הטיפול‪.‬‬
‫טבע‪ ,‬הפועלת בשיתוף עם אינטל‪ ,‬תטמיע פלטפורמה טכנולוגית חדשנית זו לראשונה בתת מחקר שנערך כחלק‬
‫ממחקר ‪ Open-Pride‬מתמשך בשלב ‪ 2‬במחלת הנטינגטון‪ .‬כחלק מכך‪ ,‬מטופלים יתבקשו להשתמש בטלפון חכם‬
‫וללבוש שעון חכם המצויד בטכנולוגיית חיישנים‪ ,‬אשר תמדוד את התנהלותם ותנועותיהם בצורה רציפה‪ .‬נתונים‬
‫אלה יוזרמו באופן אלחוטי לפלטפורמה מבוססת‪-‬ענן שפותחה על ידי אינטל במיוחד לצורך ניתוח נתונים‬
‫ממכשירים הניתנים ללבישה‪ .‬לאחר מכן‪ ,‬אלגוריתמים בלעדיים יתרגמו נתונים אלה‪ ,‬כמעט בזמן אמת‪ ,‬לציונים‬
‫אובייקטיביים של חומרת התסמינים הקשורים לתנועה‪ .‬הניסוי יתחיל לקראת סוף השנה ויתרחש במספר מרכזים‬
‫בארה"ב ובקנדה‪.‬‬
‫שיתוף הפעולה ימנף את יכולותיה של אינטל באנליטיקה ופיתוח אלגוריתמים לאבחון תנועות‪ ,‬ביחד עם הידע‬
‫והנסיון העמוקים של טבע במחקר וטיפול במחלת הנטינגטון‪ .‬הנטינגטון היא מחלה הרסנית הזקוקה באופן ממשי‬
‫לאפשרויות טיפול‪ ,‬המחייבת דרכים חדשניות ‪-‬להעריך ולמדוד את תסמיני המחלה מרחוק בצורה רציפה‪ ,‬ולהעביר‬
‫משוב חשוב ומשמעותי לרופאים‪ ,‬חולים ומטפלים‪.‬‬
‫"מטרתו של פרויקט חשוב הזה היא לספק נתונים אובייקטיביים רציפים לגבי ההשפעה של מחלת הנטינגטון על‬
‫המטופלים‪ ,‬ובצורה זו להבין בצורה טובה יותר את השפעת הטיפולים על איכות חייהם"‪ ,‬אמר מייקל היידן‪ ,‬נשיא‬
‫המו"פ הגלובלי והמדען הראשי של טבע‪" .‬מדידות התסמינים הקיימות כיום מבוססות בעיקר על אבחנות שתועדו‬
‫על ידי הרופאים במהלך ביקורים במרפאות‪ .‬טכנולוגיה זו תיתן לנו עכשיו את האפשרות לניטור מתמשך‪.‬‬
‫טכנולוגיה ייחודית זו תתמוך במחקרים עתידיים במחלת הנטינגטון"‪.‬‬
‫"מטופלים מייצרים נתונים המבוססים על ההתנסות היומיומית שלהם ואשר יכולים לסייע לשפר את ניהול המחלה‬
‫– אפילו לבישה פשוטה של שעון חכם יכולה להוסיף תובנות חשובות‪ ",‬אמר ג'ייסון ווקסמן‪ ,‬סמנכ"ל בכיר ומנהל‬
‫כללי של קבוצת מרכז המידע לפתרונות באינטל‪" .‬מורכבות ניתוח תזרימי מידע אלו מחייבת פלטפורמה של‬
‫מכונות לומדות‪ ,‬אשר עשויה להביא לניסויים קליניים מהירים וטובים יותר‪ ,‬באופן אשר טומן פוטנציאל להבאת‬
‫טיפולים טובים יותר למטופלים‪".‬‬
‫הפתרון מבוסס הענן לניתוח נתונים ממכשירים לבישים מפותח באמצעות פלטפורמת הקוד הפתוח של אינטל‪:‬‬
‫‪ ,)TAP( Trusted Analytics Platform‬פלטפורמת תוכנה המותאמת במיוחד לשיפור ביצועים ואבטחה‪ ,‬במטרה‬
‫‪(215) 591-8912‬‬
‫‪(215) 591-3033‬‬
‫‪972 (3) 926-7656‬‬
‫‪United States‬‬
‫‪United States‬‬
‫‪Israel‬‬
‫‪Kevin C. Mannix‬‬
‫‪Ran Meir‬‬
‫‪Tomer Amitai‬‬
‫‪IR Contacts:‬‬
‫‪972 (3) 926-7687‬‬
‫‪(215) 591-8974‬‬
‫‪(215) 284-0213‬‬
‫‪Israel‬‬
‫‪United States‬‬
‫‪United States‬‬
‫‪Iris Beck Codner‬‬
‫‪Denise Bradley‬‬
‫‪Nancy Leone‬‬
‫‪PR Contacts:‬‬
‫להאיץ את היצירה של פתרונות מתקדמים לניתוח נתונים ולמידת מכונה‪ .‬הפיתוח המקורי של הפלטפורמה נעשה‬
‫בשיתוף עם קרן מייקל ג'יי פוקס לשימוש בחקר מחלת פרקינסון‪.‬‬
‫אודות מחלת הנטינגטון‬
‫מחלת הנטינגטון (‪ )HD‬היא מחלה ניוונית חשוכת מרפא‪ ,‬שסימניה הם תנועות חסרות קואורדינציה או לא רצוניות‪,‬‬
‫פגיעה בתפקוד הקוגניטיבי ובעיות התנהגותיות ו‪/‬או פסיכולוגיות‪ .‬המחלה מתפרצת בדרך כלל בגיל העמידה‪ ,‬אך‬
‫מופיעה גם בקרב ילדים וקשישים‪ .‬מחלת הנטינגטון היא הגורם הגנטי הנפוץ ביותר לתנועות עוויתיות לא רצוניות‬
‫הנקראות "כוריאה" (מחולית)‪ .‬התקדמות המחלה מאופיינת בהידרדרות הדרגתית בתפקודים המוטוריים וביציבות‬
‫הקוגניטיבית והפסיכולוגית‪ ,‬וברוב המקרים מסתיימת במוות תוך ‪ 25-15‬שנים מרגע אבחון המחלה‪.‬‬
‫הנטינגטון היא מחלה גנטית המועברת מהורה לילד על ידי מוטציה גנטית‪ .‬לכל ילד להורה החולה במחלת‬
‫הנטינגטון יש סיכוי של ‪ %50‬לרשת את גן המחלה‪ .‬אם הילד לא יירש את גן המחלה‪ ,‬הוא לא יפתח אותה ולא‬
‫יוכל להעביר אותה לדורות הבאים‪ .‬אדם היורש את גן המחלה יפתח אותה בשלב כלשהו של חייו‪ .‬על פי נתוני‬
‫ארגון הבריאות העולמי (‪ ,)WHO‬מחלת הנטינגטון פוגעת בחמישה עד שבעה אנשים מתוך כל ‪ 100,000‬בעולם‬
‫המערבי‪.‬‬
‫אודות טבע‬
‫טבע תעשיות פרמצבטיות בע"מ (‪ )NYSE & TASE: TEVA‬היא חברת תרופות גלובלית המספקת פתרונות בריאות‬
‫ממוקדי‪-‬מטופל באיכות גבוהה המשמשים מיליוני מטופלים מדי יום‪ .‬טבע‪ ,‬שבסיסה בישראל‪ ,‬היא יצרנית‬
‫התרופות הגנריות הגדולה בעולם‪ ,‬הממנפת את צבר מוצריה הכולל יותר מ‪ 1,800-‬מולקולות לייצר מגוון רחב‬
‫של מוצרים גנריים ברוב התחומים הטיפוליים‪ .‬בתחום התרופות הייחודיות‪ ,‬טבע הינה חברה מובילה בטיפולים‬
‫חדשניים למחלות מערכת העצבים המרכזית‪ ,‬כולל כאב‪ ,‬והיא מחזיקה גם צבר מוצרים חזק בתחום מחלות‬
‫הנשימה‪ .‬טבע משלבת את כישוריה בתחום התרופות הגנריות ובתחום התרופות הייחודיות בחטיבת המחקר‬
‫והפיתוח הגלובלית שלה‪ ,‬במטרה ליצור דרכים חדשות לענות על צרכי המטופלים וזאת על ידי שילוב יכולות‬
‫בתחום פיתוח תרופות יחד עם פיתוח תכשירים‪ ,‬שירותים וטכנולוגיות‪ .‬הכנסות טבע בשנת ‪ 2015‬הסתכמו ב‪-‬‬
‫‪ $19.7‬מיליארד‪ .‬למידע נוסף על החברה‪ ,‬בקרו באתר ‪.www.tevapharm.com‬‬
‫‪Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:‬‬
‫‪This release contains forward-looking statements, which are based on management’s current beliefs and‬‬
‫‪expectations and involve a number of known and unknown risks and uncertainties that could cause our‬‬
‫‪future results, performance or achievements to differ significantly from the results, performance or‬‬
‫‪achievements expressed or implied by such forward-looking statements. Important factors that could‬‬
‫‪cause or contribute to such differences include risks relating to: our ability to develop and commercialize‬‬
‫‪additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which‬‬
‫‪faces competition from orally-administered alternatives and a generic version); our ability to consummate‬‬
‫‪(215) 591-8912‬‬
‫‪(215) 591-3033‬‬
‫‪972 (3) 926-7656‬‬
‫‪United States‬‬
‫‪United States‬‬
‫‪Israel‬‬
‫‪Kevin C. Mannix‬‬
‫‪Ran Meir‬‬
‫‪Tomer Amitai‬‬
‫‪IR Contacts:‬‬
‫‪972 (3) 926-7687‬‬
‫‪(215) 591-8974‬‬
‫‪(215) 284-0213‬‬
‫‪Israel‬‬
‫‪United States‬‬
‫‪United States‬‬
‫‪Iris Beck Codner‬‬
‫‪Denise Bradley‬‬
‫‪Nancy Leone‬‬
‫‪PR Contacts:‬‬
the acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”) and to
realize the anticipated benefits of such acquisition (and the timing of realizing such benefits); the fact that
following the consummation of the Actavis Generics acquisition, we will be dependent to a much larger
extent than previously on our generic pharmaceutical business; potential restrictions on our ability to
engage in additional transactions or incur additional indebtedness as a result of the substantial amount of
debt we will incur to finance the Actavis Generics acquisition; the fact that for a period of time following
the consummation of the Actavis Generics acquisition, we will have significantly less cash on hand than
previously, which could adversely affect our ability to grow; the possibility of material fines, penalties and
other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from investments in our pipeline of specialty and
other products; our ability to identify and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or
quality control problems damage our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our
exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the intellectual property rights of our specialty
medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and
coverage; competition for our generic products, both from other pharmaceutical companies and as a
result of increased governmental pricing pressures; governmental investigations into sales and marketing
practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic
instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our
supply chain or problems with internal or third-party information technology systems that adversely affect
our complex manufacturing processes; significant disruptions of our information technology systems or
breaches of our data security; competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of generic products prior to a final
resolution of outstanding patent litigation; our potential exposure to product liability claims that are not
covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and
managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment
obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting reliance on access to the capital markets;
potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or of a change in our business;
variations in patent laws that may adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form
20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and
Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they
are made and we assume no obligation to update or revise any forward-looking statements or other
information, whether as a result of new information, future events or otherwise.
IR Contacts:
Kevin C. Mannix
Ran Meir
Tomer Amitai
United States
United States
Israel
(215) 591-8912
(215) 591-3033
972 (3) 926-7656
PR Contacts:
Iris Beck Codner
Denise Bradley
Nancy Leone
Israel
United States
United States
972 (3) 926-7687
(215) 591-8974
(215) 284-0213
##
IR Contacts:
Kevin C. Mannix
Ran Meir
Tomer Amitai
United States
United States
Israel
(215) 591-8912
(215) 591-3033
972 (3) 926-7656
PR Contacts:
Iris Beck Codner
Denise Bradley
Nancy Leone
Israel
United States
United States
972 (3) 926-7687
(215) 591-8974
(215) 284-0213